Literature DB >> 1988522

Community-based treatment of onchocerciasis with ivermectin: safety, efficacy, and acceptability of yearly treatment.

M Pacqué1, B Muñoz, B M Greene, H R Taylor.   

Abstract

The safety, acceptability, and efficacy of ivermectin during community-based mass treatment of onchocerciasis was assessed. Ivermectin was distributed three times, 1 year apart, to the population of a rubber plantation (14,000 people) in Liberia where greater than 80% of adults have Onchocerca volvulus infection. In a sample of adults, the microfilarial density was reduced by 84% after 2 years of treatment. Acceptance was as high as 98% during the third year. Adverse reactions occurred in 6-13 in 1000 people after first treatment and in only 3-4 in 1000 receiving their second or third annual dose of ivermectin; severe adverse reactions were not seen. These data show that community-based treatment with ivermectin is safe, well accepted, and effective in reducing microfilarial loads and suggest that ivermectin is the first practical drug suitable for mass treatment campaigns to control human onchocerciasis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1988522     DOI: 10.1093/infdis/163.2.381

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  8 in total

1.  Pharmacologically targeting the P2rx4 gene on maintenance and reinstatement of alcohol self-administration in rats.

Authors:  Therese A Kosten
Journal:  Pharmacol Biochem Behav       Date:  2011-03-21       Impact factor: 3.533

2.  Effects of repeated ivermectin treatment in onchocerciasis.

Authors:  F L Njoo; J S Stilma; A van der Lelij
Journal:  Doc Ophthalmol       Date:  1992       Impact factor: 2.379

3.  Ivermectin-facilitated immunity in onchocerciasis. Reversal of lymphocytopenia, cellular anergy and deficient cytokine production after single treatment.

Authors:  P T Soboslay; C M Dreweck; W H Hoffmann; C G Lüder; C Heuschkel; H Görgen; M Banla; H Schulz-Key
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

4.  Ocular onchocerciasis: current management and future prospects.

Authors:  Olufemi Emmanuel Babalola
Journal:  Clin Ophthalmol       Date:  2011-10-13

5.  Establishment of the Ivermectin Research for Malaria Elimination Network: updating the research agenda.

Authors:  Carlos J Chaccour; N Regina Rabinovich; Hannah Slater; Sara E Canavati; Teun Bousema; Marcus Lacerda; Feiko Ter Kuile; Chris Drakeley; Quique Bassat; Brian D Foy; Kevin Kobylinski
Journal:  Malar J       Date:  2015-06-11       Impact factor: 2.979

6.  How does onchocerciasis-related skin and eye disease in Africa depend on cumulative exposure to infection and mass treatment?

Authors:  Natalie V S Vinkeles Melchers; Wilma A Stolk; Michele E Murdoch; Belén Pedrique; Marielle Kloek; Roel Bakker; Sake J de Vlas; Luc E Coffeng
Journal:  PLoS Negl Trop Dis       Date:  2021-06-11

Review 7.  Compliance with anthelmintic treatment in the neglected tropical diseases control programmes: a systematic review.

Authors:  Kathryn V Shuford; Hugo C Turner; Roy M Anderson
Journal:  Parasit Vectors       Date:  2016-01-27       Impact factor: 3.876

Review 8.  Ivermectin to reduce malaria transmission III. Considerations regarding regulatory and policy pathways.

Authors:  Carlos Chaccour; N Regina Rabinovich
Journal:  Malar J       Date:  2017-04-24       Impact factor: 2.979

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.